

## DESCRIPTION


<b>Species Reactivity</b>	Mouse
<b>Specificity</b>	Detects GDF-8/Myostatin Propeptide in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with mature recombinant mouse (rm) GDF-8 is observed and less than 5% cross-reactivity with mature rmGDF-1, -3, -5, -6, -7, -9, and recombinant human GDF-11 is observed.
<b>Source</b>	Polyclonal Sheep IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant mouse GDF-8/Myostatin Propeptide Asn25-Ser265 Accession # O08689
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	0.1 µg/mL	Recombinant Mouse GDF-8/Myostatin Propeptide (Catalog # 1539-PG)
<b>Neutralization</b>		Measured by its ability to neutralize GDF-8 Propeptide inhibition of GDF-8/Myostatin-dependent hemoglobin expression in the K562 human chronic myelogenous leukemia cell line. The Neutralization Dose (ND <sub>50</sub> ) is typically 10-30 µg/mL in the presence of 800 ng/mL Recombinant Mouse GDF-8 Propeptide and 40 ng/mL Recombinant Mouse GDF-8/Myostatin.

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

Growth Differentiation Factor 8 (GDF-8), also known as Myostatin, is a secreted TGF- $\beta$  superfamily protein that is expressed specifically in developing and adult skeletal muscle. It controls myoblast proliferation and is a potent negative regulator of skeletal muscle mass (1-3). Mouse GDF-8 is synthesized as a 376 amino acid (aa) preproprotein that consists of a 24 aa signal peptide, a 243 aa propeptide, and a 109 aa mature protein (2). Within the propeptide, mouse GDF-8 shares 96% and 99% aa sequence identity with human and rat GDF-8, respectively. GDF-8 is secreted as a preproprotein that is cleaved by BMP-1 family proteases to separate the 35-40 kDa propeptide from the 12 kDa bioactive mature protein (4-6). This results in a latent complex containing a disulfide-linked dimer of the mature protein and two noncovalently-associated molecules of the propeptide (2, 6). The GDF-8 propeptide functions as an inhibitor of mature GDF-8, and GDF-8 activity can also be inhibited through association with Follistatin, FLRG, Decorin, or GASP-1 (6-11). The uncleaved GDF-8 propeptide binds Latent TGF- $\beta$  bp3 which can sequester it in the extracellular matrix and prevent the proteolytic cleavage of the propeptide (12). GDF-8 binds to the type II Activin receptor Activin RIIIB which then associates with the type I receptors Activin RIB/ALK-4 or TGF-beta RI/ALK-5 to induce signaling (13). GDF-8 additionally inhibits adipogenic differentiation of mesenchymal stem cells and preadipocytes (14). Genetic deletion of GDF-8 or *in vivo* administration of the GDF-8 propeptide induces muscle hypertrophy as well as enhanced glucose utilization and insulin sensitivity and a reduction in overall fat mass (15, 16).

**References:**

1. McPherron, A.C. (2010) *Immunol. Endocr. Metab. Agents Med. Chem.* **10**:217.
2. McPherron, A.C. *et al.* (1997) *Nature* **387**:83.
3. Zimmers, T.A. *et al.* (2002) *Science* **296**:1486.
4. Wolfman, N.M. *et al.* (2003) *Proc. Natl. Acad. Sci.* **100**:15842.
5. McFarlane, C. *et al.* (2005) *Dev. Biol.* **283**:58.
6. Lee, S.J. *et al.* (2001) *Proc. Natl. Acad. Sci.* **98**:9306.
7. Thies, R.S. *et al.* (2001) *Growth Factors* **18**:251.
8. Amthor, H. *et al.* (2004) *Dev. Biol.* **270**:19.
9. Hill, J.J. *et al.* (2002) *J. Biol. Chem.* **277**:40735.
10. Miura, T. *et al.* (2006) *Biochem. Biophys. Res. Commun.* **340**:675.
11. Hill, J.J. *et al.* (2003) *Molecular Endocrinology* **17**:1144.
12. Anderson, S.B. *et al.* (2008) *J. Biol. Chem.* **283**:7027.
13. Rebbapragada, A. *et al.* (2003) *Mol. Cell. Biol.* **23**:7230.
14. Guo, W. *et al.* (2008) *J. Biol. Chem.* **283**:9136.
15. Matsakas, A. *et al.* (2009) *Neuromuscul. Disord.* **19**:489.
16. Guo, T. *et al.* (2009) *PLoS ONE* **4**:e4937.